HUE029801T2 - Kinazolinvegyületek - Google Patents

Kinazolinvegyületek Download PDF

Info

Publication number
HUE029801T2
HUE029801T2 HUE11800101A HUE11800101A HUE029801T2 HU E029801 T2 HUE029801 T2 HU E029801T2 HU E11800101 A HUE11800101 A HU E11800101A HU E11800101 A HUE11800101 A HU E11800101A HU E029801 T2 HUE029801 T2 HU E029801T2
Authority
HU
Hungary
Prior art keywords
cancer
ésére
compound
pharmaceutically acceptable
lia lia
Prior art date
Application number
HUE11800101A
Other languages
English (en)
Inventor
Weihan Zhang
Wei-Guo Su
Haibin Yang
Yumin Cui
Yongxin Ren
Xiaoqiang Yan
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of HUE029801T2 publication Critical patent/HUE029801T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Claims (4)

  1. ÁgypáEsEaii igígÁ’gayáik s... A ( ) a l'\ ..6¾ R Eg; A4a -ggls; I (:144)141¾ 1 6¾ gib rasp 6k ; k ; si skill I S >6- 51)-6 -EiaEl -se Ski'S 141¾ 4:4 6¾¾¾ ).,4 · aIöIivöI-Ih ; Hkkarki-Msnad veavsli«;; vagy kggiybi? :é-gj.-:;ö.íi?>ga-dfíí&amp; iára ' ' V . i < It. 6 ' A s V V. V i > 1* és a {.4:4 .6<4i ;-A ··)·;.s-oiinhics;:; ií-tsí;«?)-'" *í;<.üí.-\íL:?>Abolir: Av;: :· 1 ·íííí'íI·-kcA;-iîi^ pin-ski ),4t4s|pi6;;:i{A5()Î)5-· ί·^:>-..η>···4 Ytpyükgig; 6¾¾¾¾¾ kgylátié agy pyogg:5&amp;»s4rsi<'g elKsgAsilssaá kéjéi, ). Λ { is ;sE: .áiiliyiy-44-41 - ρίι6 4 fémisíiE« s-s) -7 --snss Ess lés aaiké 5 sí-aá 11 ) -1 mcsé :-il 44 sh isis ss-pi nE.kga ,4 - ' \ Ό V. \ ! ‘ S ' \ ^ ' s sK ^ i:(>Eésíp siksiís-Ess^srs
  2. 4, Λ vpgyijiél: 64-As1;|y iggglgbb Egy âykgy^.iSS'ôsïcïifegi^libgsiiiii-âU) α:4;; ;;4-s;4:s,s/4-;·: a |. IggáyaissE ·> surira, ááöi 4 rali: a kEv; -ka-ask 464:öi váÍ34;-:6:6:S:: ERggak, iyjAiyaki asgiEsaï, kréor-ukiaÈ', rak. vAEEr4k. Epliiaapisid sak és- liaskyaisívg-iayrag.
  3. 5, Λ vagyglgt ék/VMy {ággilél) égy: gyégysseigsAasliag ailagAiíháié siéja séksbniská:·.··;· a 4. Egrsyg·,ah s./r-rs::· ab-é s; rák sKAA-hus-A'SEA· 5644:64 é, 4 kEgyölsa ésivagy bgysbb ágy: gykigyásargyíseílieg Eikigsssihaie képi alkaSA:A.-:6.Aj a j. aicarpc-ns rscm·;. Ixas-bEHE lába?: égy (1.4; 6,sR ; -N-< -S-: .bc::;s4bsrE6srsEa;4- 7 ΑΐΕ:Ε,\Α;6ίΐ?6Ε6-6··Ε;· ; - asssrk-kcEibEirE-ρ!Γκ4;·;;(..6ί:|ρ;π·ί?Ι·4; 1 i I ;-kuïbAAAAiA aA: ·. ükAVá. 6f4r-Âgÿ icgAblbb égy gyxgy-sSu-rásS-rEiag ;4íé;M46AK> $614146 akaró rákaikgsas kgésrék
  4. 7, EljárM pyiäEispälis «övskarlgss EÁ-a- raci.pka lálaair «xpixîsaalsglàiîsk vagy i:y;ss>6: ískiivilásássak kr safes? gMássk'g ág I, 4gé;4y:pE?4 k?asa>:5i Aygyglaíísyk aiaVsygy lygyishé <:gy gw:g\ s.-aavs/Absy ckEgaébaíA íéglsak ssk6pE!6i4Ei4lá asvyfcygésl kikiar sEí.p-Arsal laxs:-;:? kaarssbaára ι\>λ':·.):: ka;-c\?s4. k. As I . igpnyprsí'4 sséríaiy végyÿ|sipi;k áskvagy iygglább agy gyii|ysaasáíi4EriÍ6g ellAgísáisaisI sgpEsk ;4>:ab:EíA--:\<· rák kaka lésére ykplgiiîà gysigpsas giógEjtápCgyg· 4. 4, H (gapypvESí ysslrlbb αΙΚακα.;?-;·-.. ;6igl si rali a kpvalkasék ki·?:.·: ygiasgloSE rljslérák. íri rgaks usyasal. kelsreksiés. rak. gargirák, apidsrsTiPIg rak és hayivysíiasisagyrák, 14); A 9. lgégy|Xs!b ísíaassí ígkaSrursie..akala rák geaaklSkyÜSk iegörak.
HUE11800101A 2010-06-30 2011-05-25 Kinazolinvegyületek HUE029801T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2010/074792 WO2012000182A1 (en) 2010-06-30 2010-06-30 Quinazoline compounds

Publications (1)

Publication Number Publication Date
HUE029801T2 true HUE029801T2 (hu) 2017-04-28

Family

ID=45401313

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11800101A HUE029801T2 (hu) 2010-06-30 2011-05-25 Kinazolinvegyületek

Country Status (22)

Country Link
US (1) US9168253B2 (hu)
EP (1) EP2590966B1 (hu)
JP (1) JP5736452B2 (hu)
KR (1) KR101480481B1 (hu)
AU (1) AU2011274183B2 (hu)
BR (1) BR112012033344B1 (hu)
CA (1) CA2801814C (hu)
DK (1) DK2590966T3 (hu)
ES (1) ES2604929T3 (hu)
HK (1) HK1179954A1 (hu)
HR (1) HRP20161490T1 (hu)
HU (1) HUE029801T2 (hu)
LT (1) LT2590966T (hu)
MX (1) MX2012015047A (hu)
MY (1) MY172201A (hu)
PL (1) PL2590966T3 (hu)
PT (1) PT2590966T (hu)
RS (1) RS55470B1 (hu)
RU (1) RU2530887C2 (hu)
SG (1) SG186410A1 (hu)
SI (1) SI2590966T1 (hu)
WO (2) WO2012000182A1 (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI577671B (zh) 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
WO2018099451A1 (zh) * 2016-12-01 2018-06-07 和记黄埔医药（上海）有限公司 化合物的晶型
KR101957464B1 (ko) 2018-10-18 2019-03-12 대흥전력기술 주식회사 활선 상태에서 지상기기의 점검 및 누유 보수방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CN101619043B (zh) * 2008-06-30 2013-06-05 和记黄埔医药（上海）有限公司 喹唑啉衍生物及其医药用途
US8426430B2 (en) * 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives

Also Published As

Publication number Publication date
EP2590966B1 (en) 2016-08-31
PT2590966T (pt) 2016-11-29
MX2012015047A (es) 2013-02-07
BR112012033344B1 (pt) 2020-12-15
RU2012153174A (ru) 2014-08-10
SI2590966T1 (sl) 2016-12-30
EP2590966A4 (en) 2014-01-15
AU2011274183B2 (en) 2013-09-26
RS55470B1 (sr) 2017-04-28
HRP20161490T1 (hr) 2016-12-16
KR101480481B1 (ko) 2015-01-09
ES2604929T3 (es) 2017-03-10
DK2590966T3 (en) 2016-12-19
BR112012033344A2 (pt) 2016-11-29
JP5736452B2 (ja) 2015-06-17
CA2801814C (en) 2015-04-07
JP2013529653A (ja) 2013-07-22
CA2801814A1 (en) 2012-01-05
WO2012000182A1 (en) 2012-01-05
US20130172373A1 (en) 2013-07-04
WO2012000356A1 (en) 2012-01-05
PL2590966T3 (pl) 2017-05-31
SG186410A1 (en) 2013-01-30
KR20130031358A (ko) 2013-03-28
RU2530887C2 (ru) 2014-10-20
HK1179954A1 (en) 2013-10-11
LT2590966T (lt) 2016-11-25
US9168253B2 (en) 2015-10-27
EP2590966A1 (en) 2013-05-15
AU2011274183A1 (en) 2013-01-10
MY172201A (en) 2019-11-15

Similar Documents

Publication Publication Date Title
EP1339458B1 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
KR102479693B1 (ko) 조합물
RU2423980C2 (ru) Комбинации, включающие эпотилоны и ингибиторы протеинтирозинкиназы и их фармацевтическое применение
JP6147246B2 (ja) Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法
US11851445B2 (en) Compounds and uses thereof
JP2021176819A (ja) キナゾリン化合物を有効成分とする医薬組成物
DK2590966T3 (en) quinazoline
WO2022166844A1 (en) Tricyclic compounds and uses thereof
CN102906086A (zh) 喹唑啉化合物
WO2020142745A1 (en) Methods of treating graft versus host disease and neoplastic disease with amide compounds
TWI466888B (zh) 喹唑啉化合物
WO2023009701A2 (en) Therapeutic regimens of a degrader of brd9
WO2023006954A1 (en) Asenapine for use in cancer
TW202227450A (zh) 以縮合嘧啶化合物作為有效成分之腦移行性腫瘤治療劑
US20180303797A1 (en) Chalcone Compounds
TW201202240A (en) Quinazoline compounds
JP2014034533A (ja) Ｈｓｐ９０阻害剤とｅｇｆｒチロシンキナーゼ阻害剤の組み合わせ